OptiScan, maker of glucose monitoring devices, raises $2.6M

OptiScan Biomedical pulled in $2.6 million in new funding, according to a regulatory filing. The Hayward, CA, company makes non-invasive bedside glucose monitoring devices for the hospital intensive care unit. OptiScan's SEC filing does not disclose specific investors involved or for what purpose the money will be used. But OptiScan's website notes that the company will expand the ability of its glucose monitoring devices to detect "additional analytes within the same blood sample." SEC Filing

Suggested Articles

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.